Bash Biotech

Bash Biotech is a preclinical-stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of hematological malignancies and solid tumors. The company's primary focus is on targeting Casein Kinase 1 (CK1) isoforms, specifically CK1α and CK1ε, which play critical roles in cell cycle regulation and oncogenic signaling pathways. By developing selective inhibitors, Bash Biotech aims to provide new therapeutic options for patients with aggressive cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is leveraging deep expertise in kinase biology to advance its pipeline toward clinical development.